Hydrocodone Bitartrate and Acetaminophen Tablets, USP, 10 mg/500 mg; 100 Tablets (5 x 20), 5 card...
FDA Drug Recall #D-166-2013 - Class I, December 14, 2012
Recall Summary
| Recall Number | D-166-2013 |
| Classification | Class I - Serious risk |
| Date Initiated | December 14, 2012 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Mylan Institutional, Inc. (d.b.a. UDL Laboratories) |
| Location | Rockford, IL |
| Product Type | Drugs |
| Quantity | 3,407 cartons |
Product Description
Hydrocodone Bitartrate and Acetaminophen Tablets, USP, 10 mg/500 mg; 100 Tablets (5 x 20), 5 cards each containing 20 blistered tablets per carton, Rx only; Manufactured for: Qualitest Pharmaceuticals, Huntsville, AL 35811, Pkg by & Distributed by UDL Laboratories, Inc., Rockford, IL 61103; NDC 51079-254-21.
Reason for Recall
Superpotent (Multiple Ingredient) Drug: Oversized tablets resulting in superpotent assays of both the hydrocodone and acetaminophen components.
Distribution Pattern
Nationwide
Lot / Code Information
Lot #: 3037841, 3040859, 3042573, Exp 12/13
Other Recalls from Mylan Institutional, Inc. (d.b.a. UDL...
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0861-2022 | Class II | Esomeprazole Magnesium Delayed-Release Capsules... | Apr 1, 2022 |
| D-0860-2022 | Class II | Esomeprazole Magnesium Delayed-Release Capsules... | Apr 1, 2022 |
| D-1013-2019 | Class II | Alprazolam Tablets, USP, 0.25 mg, 10x10 per car... | Jan 18, 2019 |
| D-1112-2018 | Class III | Diltiazem HCl Extended-release Capsules, USP 12... | Aug 14, 2018 |
| D-0822-2018 | Class II | Loxapine Capsules, USP 25 mg, packaged in 100 U... | May 1, 2018 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping, abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications, even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications, use a drug take-back program.